OncoMatch/Clinical Trials/NCT05183126
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
Is NCT05183126 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Paclitaxel and Paclitaxel for breast cancer.
Treatment: Paclitaxel · Paclitaxel — The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Gastric Cancer
Esophageal Carcinoma
Disease stage
Metastatic disease required
Metastatic Gastric Cancer
Lab requirements
Blood counts
Adequate organ function to receive paclitaxel treatment as defined in the protocol
Kidney function
Adequate organ function to receive paclitaxel treatment as defined in the protocol
Liver function
Adequate organ function to receive paclitaxel treatment as defined in the protocol
Adequate organ function to receive paclitaxel treatment as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Michigan Rogel Cancer Center · Ann Arbor, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify